Mirum Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $521.3M | $336.9M | $186.4M | $77.1M | $19.1M | $0 |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | — | — | — | — | — | — |
| SG&A Expense | $257.0M | $202.2M | $145.9M | $89.1M | $59.2M | $22.7M |
| Operating Income | $-22.1M | $-87.6M | $-109.2M | $-131.2M | $-173.4M | $-104.3M |
| Operating Margin | -4.2% | -26.0% | -58.6% | -170.3% | -906.1% | — |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | $-21.4M | $-86.9M | $-162.4M | $-142.1M | $-84.0M | $-103.3M |
| Income Tax Expense | $1.9M | $1.0M | $991.0K | $-6.4M | $37.0K | $6.0K |
| Net Income | $-23.4M | $-87.9M | $-163.4M | $-135.7M | $-84.0M | $-103.3M |
| Net Margin | -4.5% | -26.1% | -87.7% | -176.0% | -438.9% | — |
| EPS (Basic) | $-0.47 | $-1.85 | $-4.00 | $-4.01 | $-2.77 | $-4.09 |
| EPS (Diluted) | $-0.47 | $-1.85 | $-4.00 | $-4.02 | $-2.77 | $-4.09 |
| Shares Outstanding (Basic) | 50.2M | 47.5M | 40.9M | 33.8M | 30.3M | 29.8M |
| Shares Outstanding (Diluted) | 50.2M | 47.5M | 40.9M | 34.0M | 30.3M | 29.8M |
| Dividends Per Share | — | — | — | — | — | — |